CDA Formulations: Potentially the Standard Care of Breast, Lung and Liver Cancers

Abstract

Breast and lung cancers are very common, which are the top two leading causes of death from cancer. Hepatomas are not as common. But hepatomas are not responding well to therapies currently available. Cancer incidence and mortality keep on increasing ever since these statistics became public records, which are an indication of the failure of the health profession to control cancer. Cancer therapies approved in the past are mostly based on killing of cancer cells which are wrong to solve only a fraction of cancer problems. To effectively solve cancer, we must eliminate all factors contributing to the evolution of cancer. Cancer evolves due to wound unhealing because of the collapse of chemo-surveillance. Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs), which are embryonic stem cells to initiate the development of organs and tissues. Methylation enzymes (MEs) play a pivotal role on the regulation of cell replication and differentiation. Because of this pivotal role, MEs are exceptionally subjected to double allosteric regulations, on the individual enzymes by steroid hormone and on the enzyme complex by telomerase and chemo-surveillance. MEs of embryonic stem cells (ESCs) including PSCs are abnormal due to association with telomerase, which are important for the functions of these cells for the development of fetus and wound healing. The build-up of normal stem cells with abnormal MEs is strictly under regulations by contact inhibition, ten-eleven translocator -1 (TET-1) enzyme to direct lineage transitions and chemo-surveillance to destabilize abnormal MEs. When such safety mechanisms fail, clinical symptoms arise. Obviously, the most appropriate solution of diseases due to wound unhealing is to restore safety mechanisms created by the nature. Cell differentiation agent -2 (CDA-2) is our creation of cancer drug to target on abnormal MEs. CDA-2 was approved by the Chinese FDA as an adjuvant to supplement cytotoxic therapy of cancer against breast, non-small cell lung cancers and primary hepatomas in 2004, and as a mono-therapeutic agent for the therapy of myelodysplastic syndromes (MDSs) in 2017. MDSs are diseases attributable entirely to cancer stem cells (CSCs). CDA-2 was the best drug for the therapy of MDSs, and therefore should be considered the standard care of MDSs. Breast, non-small cell lung cancers and primary hepatomas responded well to CDA-2. The therapeutic end point of CDA-2 is the terminal differentiation of cancer cells which cannot make tumor to disappear. Evidently, terminal differentiation of CSCs is the only option to solve CSCs. The solution of CSCs is very critical to the success of cancer therapy. Therefore, CDA formulations are potentially the standard care of breast and lung cancers and primary hepatomas.